549 related articles for article (PubMed ID: 29760047)
21. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
22. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
23. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
24. CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
Knochelmann HM; Smith AS; Dwyer CJ; Wyatt MM; Mehrotra S; Paulos CM
Front Immunol; 2018; 9():1740. PubMed ID: 30140266
[TBL] [Abstract][Full Text] [Related]
25. [Not Available].
Alcazer V; Delenda C; Poirot L; Depil S
Bull Cancer; 2018 Dec; 105 Suppl 2():S178-S187. PubMed ID: 30686356
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
27. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
Tang XY; Ding YS; Zhou T; Wang X; Yang Y
Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
[TBL] [Abstract][Full Text] [Related]
28. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
29. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor.
Ma L; Dichwalkar T; Chang JYH; Cossette B; Garafola D; Zhang AQ; Fichter M; Wang C; Liang S; Silva M; Kumari S; Mehta NK; Abraham W; Thai N; Li N; Wittrup KD; Irvine DJ
Science; 2019 Jul; 365(6449):162-168. PubMed ID: 31296767
[TBL] [Abstract][Full Text] [Related]
30. Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.
Fucà G; Reppel L; Landoni E; Savoldo B; Dotti G
Clin Cancer Res; 2020 Jun; 26(11):2444-2451. PubMed ID: 32015021
[TBL] [Abstract][Full Text] [Related]
31. CAR-T cells: the long and winding road to solid tumors.
D'Aloia MM; Zizzari IG; Sacchetti B; Pierelli L; Alimandi M
Cell Death Dis; 2018 Feb; 9(3):282. PubMed ID: 29449531
[TBL] [Abstract][Full Text] [Related]
32. [T cell-based immunotherapies in solid tumors].
Baulu E; Dougé A; Chuvin N; Bay JO; Depil S
Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
[TBL] [Abstract][Full Text] [Related]
33. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
34. An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment.
Wang Y; Jiang H; Luo H; Sun Y; Shi B; Sun R; Li Z
Front Immunol; 2019; 10():1691. PubMed ID: 31379876
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
36. Gene modification strategies for next-generation CAR T cells against solid cancers.
Tian Y; Li Y; Shao Y; Zhang Y
J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
[TBL] [Abstract][Full Text] [Related]
37. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
38. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
39. The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.
Deng C; Zhao J; Zhou S; Dong J; Cao J; Gao J; Bai Y; Deng H
Mol Ther; 2020 Jan; 28(1):75-88. PubMed ID: 31672285
[TBL] [Abstract][Full Text] [Related]
40. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
